Interfaculty Institute of Microbiology and Infection Medicine

Prof. Dr. rer. nat. Lisa Maier

M3 Research Center
Interfaculty Institute of Microbiology and Infection Medicine
Otfried-Müller-Straße 37
72076 Tübingen



Lisa Maier is a biochemist by training and received her doctorate in 2014 from ETH Zurich, Switzerland. During her PhD in the lab of Prof. Wolf-Dietrich Hardt, she investigated the role of the microbiome in Salmonella infections. As part of the interdisciplinary postdoctoral program at EMBL in Heidelberg, she worked with Dr. Athanasios Typas and Dr. Kiran Patil on high-throughput methods for the systematic investigation of drug-microbiome interactions. In 2019, supported by the Emmy Noether Program of the German Research Foundation, she established her independent research group at the Interfaculty Institute of Microbiology and Infection Medicine Tübingen. In 2022, she was awarded a Starting Grant from the European Research Council and accepted a call to a full professorship at the Medical Faculty of the University of Tübingen. Her lab is integrated into the Cluster of Excellence "Controlling Microbes to Fight Infections" and the interdisciplinary M3 (Malignoma-Metabolome-Microbiome) Research Institute in Tübingen.


Drug-Microbiome-Host Interactions

The  long-term research goal is to gain a detailed and comprehensive understanding of the role of the gut microbiota in health and disease. 

In recent years, we have developed a particular interest in the effects of medicinal drugs on the human gut microbiome. To understand the interactions between small molecules, the microbiome and the host, thelab uses microbiology-driven and cultivation-based bottom-up approaches. As a starting point, the team systematically maps the direct effects of drugs on gut bacteria in pure cultures, in microbial communities and in vivo. Based on the results of these systematic approaches, the team elucidates the underlying molecular mechanisms, investigates the development of resistance and explores the consequences for the host, such as drug efficacy, toxicity, pathogen colonisation or side effects. The current focus is on anticancer and psychotropic drugs, as these therapeutic drug classes show strong direct effects on the gut microbiome.

We are further using our insights into how small molecules modulate the gut microbiome to develop strategies for targeted pathogen decolonisation. For example, the lab aims to reverse ectopic colonisation of the gut with species from the oropharyngeal cavity - a scenario that has been shown to cause enteric environmental dysfunction (EED), is associated with chronic malnutrition in children and linked to colorectal cancer. 

In addition, the lab is developing methods and protocols for isolating, culturing and investigating previously under-studied members of the human microbiome. This includes developing tools to illuminate the genomic dark matter of the human gut microbiome.

visit us for more information